Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT07130903. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT07130903
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- Fruquintinib Drug
- TheraBionic P1 Device
Drug · Device
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2025
- Primary completion
- Apr 16, 2028
- Completion
- Apr 16, 2030
- Last update posted
- Nov 9, 2025
2025 – 2030
United States locations
- U.S. sites
- 9
- U.S. states
- 1
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Karmanos Cancer Institute at McLaren Bay Region | Bay City | Michigan | 48706 | Recruiting |
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston | Michigan | 48346 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint | Michigan | 48532 | Recruiting |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan | 48910 | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer | Michigan | 48446 | Recruiting |
| Karmanos Cancer Institute at McLaren Macomb | Macomb | Michigan | 48043 | Recruiting |
| Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey | Petoskey | Michigan | 49770 | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron | Michigan | 48060 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07130903, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07130903 live on ClinicalTrials.gov.